Can Reference Sponsor Forfeit Right To Sue Under BPCIA?
In Amgen Inc. v. Apotex Inc.,[1] the Federal Circuit addressed the 180-day notice provision of the Biologics Price Competition and Innovation Act of 2009 where the parties had engaged in the so-called...To view the full article, register now.
Already a subscriber? Click here to view full article